GLP1R and Alzheimer disease: According to preclinical studies, GLP-1 receptor agonists may increase cognitive function, reduce neuronal loss, and improve behavioral symptoms in animal models of AD, thus providing a hopeful, creative approach for treating AD (Sweeney et al. 2023).